SG11202009372UA - Systems and methods for quantifying and modifying protein viscosity - Google Patents
Systems and methods for quantifying and modifying protein viscosityInfo
- Publication number
- SG11202009372UA SG11202009372UA SG11202009372UA SG11202009372UA SG11202009372UA SG 11202009372U A SG11202009372U A SG 11202009372UA SG 11202009372U A SG11202009372U A SG 11202009372UA SG 11202009372U A SG11202009372U A SG 11202009372UA SG 11202009372U A SG11202009372U A SG 11202009372UA
- Authority
- SG
- Singapore
- Prior art keywords
- quantifying
- systems
- methods
- modifying protein
- protein viscosity
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4005—Concentrating samples by transferring a selected component through a membrane
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4005—Concentrating samples by transferring a selected component through a membrane
- G01N2001/4016—Concentrating samples by transferring a selected component through a membrane being a selective membrane, e.g. dialysis or osmosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862669440P | 2018-05-10 | 2018-05-10 | |
PCT/US2019/031438 WO2019217626A1 (en) | 2018-05-10 | 2019-05-09 | Systems and methods for quantifying and modifying protein viscosity |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202009372UA true SG11202009372UA (en) | 2020-10-29 |
Family
ID=66794086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202009372UA SG11202009372UA (en) | 2018-05-10 | 2019-05-09 | Systems and methods for quantifying and modifying protein viscosity |
Country Status (14)
Country | Link |
---|---|
US (1) | US20190345196A1 (en) |
EP (1) | EP3791189A1 (en) |
JP (1) | JP2021523349A (en) |
KR (1) | KR20210007958A (en) |
CN (1) | CN112136049A (en) |
AR (1) | AR115383A1 (en) |
AU (1) | AU2019266275A1 (en) |
BR (1) | BR112020021140A2 (en) |
CA (1) | CA3095190A1 (en) |
EA (1) | EA202092694A1 (en) |
MX (1) | MX2020012016A (en) |
SG (1) | SG11202009372UA (en) |
TW (1) | TW202016125A (en) |
WO (1) | WO2019217626A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022187323A1 (en) * | 2021-03-03 | 2022-09-09 | Regeneron Pharmaceuticals, Inc. | Systems and methods for quantifying and modifying protein viscosity |
WO2024208261A1 (en) * | 2023-04-04 | 2024-10-10 | 南京金斯瑞生物科技有限公司 | Viscosity prediction method for antibody drug development |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
KR100659477B1 (en) * | 1999-06-08 | 2006-12-20 | 리제네론 파라마큐티칼스 인코포레이티드 | Modified chimeric polypeptides with improved pharmacokinetic properties |
JP4340062B2 (en) * | 2000-10-12 | 2009-10-07 | ジェネンテック・インコーポレーテッド | Concentrated protein preparation with reduced viscosity |
TW574597B (en) | 2002-03-08 | 2004-02-01 | Asml Netherlands Bv | Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method |
ES2377579T3 (en) | 2006-06-02 | 2012-03-29 | Regeneron Pharmaceuticals, Inc. | High-affinity antibodies against the human IL-6 receptor |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
JP5588865B2 (en) | 2007-07-31 | 2014-09-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Human antibodies against human CD20 and methods of use thereof |
US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
JO3672B1 (en) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | High Affinity Human Antibodies to PCSK9 |
MX342623B (en) | 2009-06-26 | 2016-10-06 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format. |
JO3417B1 (en) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies |
JO3340B1 (en) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | Antibodies to human gdf8 |
JOP20190250A1 (en) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | Stable formulas containing anti-NGF antibodies |
AR083044A1 (en) | 2010-09-27 | 2013-01-30 | Regeneron Pharma | ANTI-CD48 ANTIBODIES AND USES OF THE SAME |
NZ609557A (en) | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
JO3756B1 (en) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | Human antibodies to the glucagon receptor |
AR087329A1 (en) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | HUMAN ANTIBODIES AGAINST PROTEIN 3 OF HUMAN ANGIOPOIETIN TYPE |
AU2012339722B2 (en) | 2011-11-14 | 2017-09-14 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A |
JO3533B1 (en) | 2012-01-23 | 2020-07-05 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies |
JO3820B1 (en) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | Human antibodies to FEL D1 and methods for their use |
TW201843172A (en) | 2012-06-25 | 2018-12-16 | 美商再生元醫藥公司 | anti-EGFR antibody and use thereof |
CN104540852B (en) | 2012-08-13 | 2018-10-02 | 瑞泽恩制药公司 | Anti- PCSK9 antibody with pH- dependence binding characteristics |
JOP20200236A1 (en) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
JO3405B1 (en) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF |
JO3532B1 (en) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | Anti-il-33 antibodies and uses thereof |
TWI659968B (en) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | Human antibodies to respiratory syncytial virus f protein and methods of use thereof |
CN105007929B (en) | 2013-03-15 | 2019-05-10 | 瑞泽恩制药公司 | IL-33 antagonist and its purposes |
TWI641620B (en) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | Anti-prlr antibodies and uses thereof |
TWI680138B (en) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | Human antibodies to pd-l1 |
TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
US9475875B2 (en) | 2014-03-11 | 2016-10-25 | Regeneron Pharmaceuticals, Inc. | Anti-EGFRvIII antibodies and uses thereof |
TWI754319B (en) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | Methods and antibody compositions for tumor treatment |
CA3225091A1 (en) | 2014-05-05 | 2015-11-12 | Regeneron Pharmaceuticals, Inc. | Humanized c5 and c3 animals |
JO3701B1 (en) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | Human antibodies to middle east respiratory syndrome – coronavirus spike protein |
SG11201701711VA (en) | 2014-09-16 | 2017-04-27 | Regeneron Pharma | Anti-glucagon antibodies and uses thereof |
US10894818B2 (en) * | 2014-10-03 | 2021-01-19 | Massachusetts Institute Of Technology | Antibodies that bind Ebola glycoprotein and uses thereof |
JP2017536833A (en) * | 2014-12-01 | 2017-12-14 | ザ スクリプス リサーチ インスティテュート | Methods and compositions related to functional polypeptides incorporated into heterologous protein scaffolds |
TWI710573B (en) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | Human antibodies to ebola virus glycoprotein |
-
2019
- 2019-05-08 TW TW108115831A patent/TW202016125A/en unknown
- 2019-05-09 BR BR112020021140-0A patent/BR112020021140A2/en unknown
- 2019-05-09 EP EP19729401.0A patent/EP3791189A1/en not_active Withdrawn
- 2019-05-09 US US16/407,414 patent/US20190345196A1/en not_active Abandoned
- 2019-05-09 CN CN201980030823.XA patent/CN112136049A/en active Pending
- 2019-05-09 SG SG11202009372UA patent/SG11202009372UA/en unknown
- 2019-05-09 EA EA202092694A patent/EA202092694A1/en unknown
- 2019-05-09 JP JP2020560157A patent/JP2021523349A/en active Pending
- 2019-05-09 AU AU2019266275A patent/AU2019266275A1/en not_active Abandoned
- 2019-05-09 KR KR1020207030233A patent/KR20210007958A/en not_active Withdrawn
- 2019-05-09 WO PCT/US2019/031438 patent/WO2019217626A1/en active Application Filing
- 2019-05-09 MX MX2020012016A patent/MX2020012016A/en unknown
- 2019-05-09 CA CA3095190A patent/CA3095190A1/en active Pending
- 2019-05-10 AR ARP190101253A patent/AR115383A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20210007958A (en) | 2021-01-20 |
EP3791189A1 (en) | 2021-03-17 |
AR115383A1 (en) | 2021-01-13 |
CA3095190A1 (en) | 2019-11-14 |
AU2019266275A1 (en) | 2020-11-05 |
BR112020021140A2 (en) | 2021-02-17 |
MX2020012016A (en) | 2021-01-29 |
JP2021523349A (en) | 2021-09-02 |
CN112136049A (en) | 2020-12-25 |
US20190345196A1 (en) | 2019-11-14 |
WO2019217626A1 (en) | 2019-11-14 |
EA202092694A1 (en) | 2021-03-12 |
TW202016125A (en) | 2020-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202100588SA (en) | Systems and methods for metabolome analysis | |
SG11201811762RA (en) | Systems and methods for path determination | |
ZA202003999B (en) | System and methods | |
EP3669306A4 (en) | System and method for identifying vaping and bullying | |
SG11202008774YA (en) | Electrohydrodynamic bioprinter system and method | |
IL272228B2 (en) | System and Method for Non-Invasively Determining Egg Properties | |
IL290612A (en) | Systems and methods for predicting proteins | |
EP3805726A4 (en) | Inspection system and inspection method | |
GB201804807D0 (en) | Interaactive systems and methods | |
GB201807293D0 (en) | Biosensor method and system | |
EP3829812A4 (en) | Minimum quantity lubrication system and method | |
GB2572956B (en) | Calibration system and method | |
GB2572677B (en) | System and method | |
IL291284A (en) | Systems and methods for protein expression | |
EP3874580A4 (en) | System and method for determining q factor | |
IL276102A (en) | System and method for characterizing protein dimerization | |
EP3815028A4 (en) | Method and system for risk determination | |
IL257059B (en) | Multi-beamforming system and method | |
SG11202009372UA (en) | Systems and methods for quantifying and modifying protein viscosity | |
GB201816668D0 (en) | System and method | |
GB201809582D0 (en) | System and method | |
GB201801922D0 (en) | Surrogate neck and method | |
GB201803940D0 (en) | Methods and systems for analysis | |
IL257582B (en) | Conveyors interfacing system and method | |
GB2576029B (en) | Illumination system and method |